CoChat
Sign Up
Cited by 9Colorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; the references it cites are not checked yet.

LBA-01 Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)

Open access
Bendell, J., Tae Won, K., Cheng Ean, C., Yung-Jue, B., Lee, C., Desai, J., Lewin, J., Wallin, J., Das Thakur, M., Mwawasi, G., Cha, E., Infante, J.·2016·Annals of Oncology
DOI 10.1093/annonc/mdw237.01
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw237.01

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Early-phase clinical trials evaluating afatinib with selumetinib, dacomitinib with PD-0325901, and cobimetinib with atezolizumab failed to prove efficacy.

    “Early-phase clinical trials evaluating combinations such as afatinib (a pan-HER inhibitor) with selumetinib (a MEK inhibitor), dacomitinib (a panHER inhibitor) with PD-0325901 (a MEK1/2 inhibitor), and cobimetinib (a MEK inhibitor) with atezolizumab (an anti-PDL1), have failed to prove efficacy [78,79,80].”

    From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [80]

Citations

The citation lists haven’t been fetched yet

Cited by 9

Metadata

Authors
Bendell, J., Tae Won, K., Cheng Ean, C., Yung-Jue, B., Lee, C., Desai, J., Lewin, J., Wallin, J., Das Thakur, M., Mwawasi, G., Cha, E., & Infante, J.
Affiliations
  • Sarah Cannon (US)
  • University of North Carolina at Chapel Hill (US)
  • The Royal Melbourne Hospital (AU)
  • University Health Network (CA)
  • Genentech (US)
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2016-06
Volume
27
Pages
ii140
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdw237.01
OpenAlex
W2493288410
Cited by
9
References
0
Citations by year
2025: 1 · 2021: 1 · 2019: 2 · 2017: 5
Type
conference abstract
Language
en
Open access
Licence
Locations
Annals of Oncology (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
cobimetinib, atezolizumab, metastatic colorectal cancer, MEK inhibition, PD-L1 blockade, immune checkpoint inhibitor combination, microsatellite stable tumors, microsatellite instability, KRAS wild-type, dose escalation, safety and tolerability, tumor response, immune response biomarkers, anti-PD-1 resistance, predictive biomarkers, PD-L1 expression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review